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Objectives: The aim of this study is to compare the total cost of subcutaneous 
trastuzumab (SC-TRA) vs intravenous trastuzumab (IV-TRA) for HER2+ breast cancer 
patients from the R. Macedonia. Recent studies suggest that SC-TRA has a pharma-
cokinetic profile and efficacy non-inferior to standard IV-TRA and is a valid alternative 
for the treatment of eligible breast cancer patients. MethOds: A cost-minimization 
analysis was performed using data from prior prospective time-motion study. Total 
time and cost of both types of TRA administration were quantified in a time horizon 
of over 18 cycles therapy course.The total of 169 patients (mean weight 74.20 kg) (300 
observed episodes) from two oncology clinics were enrolled. Patients were HER2+ and 
received the drug in the adjuvant (132 patients) or first line metastatic (37 patients) 
setting. Health care resources included drug treatment, patient’s room and chair time 
treatments, active healthcare professional time and consumables. Non-health care 
resources encompassed patients’ transport. The model accounted the 3%wastage of 
IV-TRA administration. Unit costs were obtained utilizing official (government and 
hospital pharmacy) publicly available data and they were expressed in Euro 2015, with 
no discount. Results: Direct medical costs per (mean weight) patient were € 30 500 
for IV-TRA and € 30 102 for SC-TRA. The mean total costs per patient of IV compared 
to SC administratuin of TRA over the full course of treatment were € 30 695 and € 30 
106, respectively. SC-TRA incurred less non-drug related cost (€ 4,20) than IV-TRA 
(€ 196). The results of the model were most sensitive to patient weight and % of wast-
age in IV treated patients. Mean cost saving per patient over a full treatment course 
for SC administration was € 589,2. Mean savings (preparation and administration) in 
time with SC-TRA were 47 min. cOnclusiOns: SC-TRA can be time and cost-saving 
therapy for HER2+ breast cancer patients from the R. Macedonia.
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Objectives: To determine the preferable treatment scheme for breast cancer (BC) 
from the pharmacoeconomic perspective by the comparison of subcutaneous (SC) 
and intravenous (IV) administration. MethOds: The following pharmacoeconomic 
methods were used: cost-minimization analysis, budget impact analysis. Results: 
For cost-minimization analysis the following costs were included: cost of testing on 
tumor expression of HER2, the main drug therapy, concomitant therapy (medical 
services and drugs), introduction, services provided by medical personnel and the 
conditions of administration (in case of hospitalization or outpatient). Total costs per 
1 patient with BC for treatment course with trastuzumab for subcutaneous admin-
istration were 1 314 181 RUB/21 863 EUR and 1 503 716 RUB/25 016 EUR of trastu-
zumab for IV administration. Cost-minimization analysis revealed treatment change 
from trastuzumab for IV administration on trastuzumab for SC administration gave 
economy of 189 535 RUB/3 153 EUR per 1 patient for treatment course. According 
to budget impact analysis it was revealed that trastuzumab for SC administration 
allows to make economy of 175 508 955 RUB/2 919 796 EUR. cOnclusiOns: During 
cost-minimization analysis it is determined that trastuzumab for IV allows to obtain 
economy compared with IV dosage form. Budget impact analysis reveals that change 
of BC treatment from trastuzumab for IV administration on trastuzumab for SC one 
give monetary economy.
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Objectives: To determine the most preferable from the pharmacoeconomic per-
spective treatment scheme of follicular lymphoma (FL) treatment with rituximab for 
subcutaneous (SC) and intravenous (IV) administration. MethOds: For this objective, 
the following pharmacoeconomic methods were used: cost-minimization analysis, 
budget impact. Results: The following costs were calculated for cost-minimization 
analysis: the main drug therapy, concomitant therapy, including medical services 
and medicines, administration, services provided by medical personnel and the 
conditions of administration (outpatient or hospitalization). According to the cost 
analysis it was determined that cost of FL treatment equals 3 534 687 RUB/ 58 803 
EUR under IV administration and 3 498 840 RUB/58 207 EUR under SC one. Cost-
minimization analysis revealed that rituximab for SC administration compared with 
IV one gives economy of 35 847 RUB/ 596 EUR per one patient for treatment course. 
During budget impact analysis it was determined that rituximab for SC administra-
tion gives 177 083 678 RUB/ 2 945 994EUR economy for treatment course of all patients 
in Russia. cOnclusiOns: According to cost-minimization analysis, subcutaneous 
dosage form of rituximab allows to obtain economy compared with intravenous form. 
Budget impact analysis shows that rituximab for subcutaneous administration allows 
to make economy.
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tHeraPy
expected to prevent an even broader spectrum of HPV-related cancers and other 
diseases and in particular, 90% of cervical cancers. This objective of this study was to 
estimate the incremental public health impact of a girls-only vaccination program 
with that of a universal vaccination program with a nonavalent human papillo-
mavirus vaccine in Germany as compared to the current girls-only vaccination 
with a quadrivalent HPV vaccine (6/11/16/18). MethOds: A dynamic transmission 
model of HPV infection and the related diseases was calibrated to the German 
epidemiological data. Up to 70% of cervical cancer cases were attributed to HPV 
16/18 for the quadrivalent vaccine, and an additional 20% to the five additional 
types included in the nonavalent vaccine. In the base case, a two dose vaccination 
program with lifelong protection and a cumulative vaccination coverage rate of 
55.6% was assumed. Sensitivity analyses were conducted. Results: The findings 
of the analyses indicate that girls-only vaccination with the nonavalent vaccine 
has the potential to: i) reduce the incidence of HPV16/18/31/33/45/52/58 -related 
cervical cancer by 73% after 100 years, relative to 57% for the quadrivalent vaccine 
and , ii) prevent an additional of 345,627 cases of CIN2/3 and 25,566 cases of cervical 
cancer over 100 years. When vaccination of girls with the nonavalent vaccine was 
extended to boys, the cumulative reduction over 100 years in the incident cases 
was 498,007 and 39,489 of CIN2/3 and cervical cancer respectively. cOnclusiOns: 
The introduction of a nonavalent HPV vaccine immunization program in Germany 
is estimated to significantly reduce the public health impact of cervical and other 
HPV-related diseases.
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Objectives: Evidence suggests that response-guided neoadjuvant chemotherapy 
(RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestro-
gen receptor positive/human epidermal growth factor receptor-2 negative (ER+/
HER2-) breast cancer patients. We estimated the expected cost-effectiveness and 
resource requirements of implementing RG-NACT with MRI vs. conventional-NACT 
for treatment of ER+/HER2- breast cancers in the Netherlands (NL). MethOds: A 
Markov-model was developed to analyse the incremental costs/QALY from a hos-
pital perspective over a 5-year time horizon. Health services required (MRI scans 
performed, MRI technologists, breast radiologists and confirmatory scans) for and 
health outcomes (prevented relapses, prevented deaths, patients with adverse 
events or contraindications and MRI technologists with adverse events) of imple-
menting RG-NACT were estimated via resource modelling analysis considering the 
current (4%) and a full implementation (100%) scenario in the Dutch population of 
ER+/HER2- breast cancer women (n= 6306). Results: RG-NACT is expected to gener-
ate 0.001 and 0.07 QALYs and save € 8 and € 341 costs for the 4% and 100% implemen-
tation scenarios respectively. At current implementation rate, 213 MRI examinations, 
273 MRI technologists and 1 breast radiologist are required to prevent 0.4 relapses 
and 6 cancer deaths. At full implementation, a 25-fold increase in MRI examina-
tions is projected, requiring ~5 times higher MRI utilization and 6560 additional MRI 
technologists, which is expected to prevent 10 additional relapses (+2400%) and 169 
cancer deaths (+2400%). Increasing implementation rates markedly increased the 
number of confirmatory scans (+901), contraindications (+932) and MRI technolo-
gists experiencing adverse events (+1706) by 25-fold, and decreased the number 
of patients with adverse events (-29) by 1.3-fold. cOnclusiOns: RG-NACT likely 
dominates conventional-NACT at current and full implementation rates. Full imple-
mentation generates a 25-fold increase in additional health benefits, but requires 
MRI capacity in the Netherlands to be increased 5-fold, which is challenging given 
a shortage of MRI technologists.
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Objectives: The main objective for conducting this study was to evaluate economic 
evaluation through the cost-effectiveness study of oral chemotherapy regimens 
we choose vinorelbine oral capsule plus oral capecitabine versus docetaxel iv plus 
oral capecitabine in treatment of metastatic breast cancer, in the Egyptian patients 
previously treated with anthracycline, from the national fund perspective over a 
time horizon of 3 years. MethOds: A cost-effectiveness analysis from the perspec-
tive of the Ministry of Health and Population was conducted. A Markov model was 
applied with three health states. Utility data were incorporated in the model to make 
adjusted results. Costs used were the local ones according to the national fund list. 
Discounting was applied at 3.5% annually both on costs and benefits. The results 
obtained were in term of ICER and number of QALYs. Robustness of our findings 
was checked using sensitivity analyses. Results are expressed in QALYs Results: 
During the three-year time horizon, the total cost for oral chemotherapy regimen 
vinorelbine oral plus capsitabine was associated with a 2.46QALY gained. The total 
for docetaxel IV. was associated with 0.84 QALY gained.That yields a difference of 
and 1.62 in QALY. The oral chemotherapy regimen( Vinorelbine oral plus capsitabine 
is economically dominating the docetaxel strategy, producing more benefit at a 
lower cost. The one-dimensional sensitivity analysis indicated that the overall sur-
vival medians of both drugs had the largest impact on the results. When conducting 
sensitivity analysis using plausible ranges, Vinorelbine oral remained economically 
dominant in all cases. cOnclusiOns: The introduction of oral chemotherapy regi-
men in metastatic breast cancer vinorelbine oral to the national fund Pay-at-The-
Expense-of-the-State (PTES) system was likely be cost saving based strictly from 
its perspective.
